Skip to content

A non-inferiority randomized control trial of radiofrequency ablation for recurrent/metastasis papillary thyroid carcinoma on the neck after thyroidectomy: comparison with surgery

A non-inferiority randomized control trial of radiofrequency ablation for recurrent/metastasis papillary thyroid carcinoma on the neck after thyroidectomy: comparison with surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059657
Enrollment
Unknown
Registered
2022-05-05
Start date
2022-07-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent/metastasis papillary thyroid carcinoma on the neck

Interventions

Radiofrequency ablation:Radiofrequency ablation

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The primary tumor is thyroid papillary carcinoma; 2. The first treatment was total thyroidectomy+lymphadenectomy; 3. The first rmPTC lesion in the neck was diagnosed by the following means: 1) At the same time, three imaging methods (neck ultrasound, neck and chest CT and iodine 131 whole-body scan) were performed, and at least two imaging methods were used to diagnose neck rmPTC; 2) The largest lesion was confirmed by fine needle aspiration biopsy; 4. Neck rmPTC with localized lesions: 1) Located in the ipsilateral neck; 2) = 5 lesions; 3) The maximum diameter of lymph nodes is 8-30mm; 4) No distant metastasis was found in imaging examination; 5. = 18 years old.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Laryngoscope indicates contralateral vocal cord dysfunction; 3. Coagulation dysfunction and organ dysfunction; 4. There is no suitable puncture and ablation path; 5. Failure to follow up on schedule; 6. Have a history of mental disorders, personality disorders, cognitive disorders, and brain organic diseases.

Design outcomes

Primary

MeasureTime frame
5-year recurrence-free survival;

Secondary

MeasureTime frame
overall survival;disease-specific survival;response;complication;serum Tg;quality of life;

Countries

China

Contacts

Public ContactJie Ren

The Third Affiliated Hospital of Sun Yat-sen University

renj@mail.sysu.edu.cn+86 13925155583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026